InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by Claire de Lingua de Saint Blanquat, Vice-Présidente, Affaires Juridiques et Corporate et Secrétaire du Conseil. Insider active across 1 companies, notably Innate Pharma. Cumulatively, 2 filings have been logged. Total volume traded: €40k. The latest transaction was filed on 31 December 2025 — Acquisition. Regulator: AMF. All data is free.
Declarations2 total
€40,20025,000 shares@ €1.6080.027% mcap100.0% of flow
ActionEuronext Paris
2026DD1086813·
Ideal exit: 27 Sept 2026 (T+270)
028,000 shares0
Actions gratuitesHors plateforme de négociation
2025DD1015979·
Ideal exit: 27 Sept 2025 (T+270)
2 of 2 declarations
About Claire de Lingua de Saint Blanquat
Claire de Lingua de Saint Blanquat is Vice President, Legal and Corporate Affairs, and Secretary of the Board at Innate Pharma. In this capacity, she plays a central role in the governance of a listed biopharmaceutical company, where legal oversight, regulatory compliance, corporate governance, and stakeholder coordination are critical. Her responsibilities sit at the intersection of board process, corporate secretarial duties, risk management, and support to senior leadership on strategic and compliance matters. She joined Innate Pharma in October 2020 and was appointed to the Executive Committee in January 2023, reflecting the growing strategic importance of her role within the company. Before joining Innate Pharma, she built nearly 20 years of experience in legal positions across the pharmaceutical industry. Admitted to the Paris Bar in 1998, she began her career at Clifford Chance and later held senior roles at Teva, Servier, and Biogaran. At Biogaran, she served as Legal and Compliance Director from 2016. Her background shows a strong specialization in business law applied to healthcare, with deep expertise in compliance, governance, and legal risk management in regulated industries. She holds a master’s degree in private law from Paris II Panthéon-Assas, a DEA in civil and commercial obligations law from Paris V, and a DESS in biotechnology law from Versailles-Saint-Quentin University. This combination of legal education and sector experience positions her at the crossroads of corporate law, strategic decision-making, and the specific demands of biotech and pharmaceutical companies. At Innate Pharma, her expertise supports sensitive governance decisions and the company’s corporate evolution. The company’s transition in May 2025 from an executive board/supervisory board structure to a board of directors with a chief executive officer marked a major governance milestone, a context in which strong legal and corporate functions are especially important.
